Benzimidazole as Novel Therapy for Hormone-Refractory Metastatic Prostate Cancer

摘要

The focus of this project is to evaluate the anti-tumor effects of benzimidazoles as a potential anti-metastatic prostate cancer therapy. We identified benzimidazoles, a class of anti-parasitic drug, in a drug screening process for preferential anti-tumor activity on metastatic prostate cancer cells. We demonstrated that benzimidazoles have potent anti-tumor activities, mediated through cell cycle arrest and induction of apoptosis. Our data indicates that benzimidazole treatment prolong the survival length of mice bearing prostate cancer metastases, inhibit the growth of prostate cancer cells growing in the bone microenvironment and more profoundly, remain active against paclitaxel-resistant prostate cancer tumors. This study further supports the use of benzimidazoles as potent anticancer therapy for men with metastatic prostate cancer.